PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake.
The effect of multiple patient-related factors on the degree of cardiac 18F-FDG uptake was assessed.


METHODS
Five hundred four consecutive patients undergoing routine 18F-FDG PET/CT studies completed a clinical questionnaire. 18F-FDG uptake was measured as the mean standardized uptake value within the heart delineated on the CT component of the study. Univariate and multivariate analyses assessed the influence of 51 clinical factors on cardiac 18F-FDG uptake.


RESULTS
On both multivariate and univariate analyses, cardiac 18F-FDG uptake was significantly lower in diabetics and in patients receiving bezafibrate or levothyroxine. Cardiac 18F-FDG uptake was significantly higher in men, patients younger than 30 y old, fasting duration of <5 h, patients with heart failure, and those receiving benzodiazepines.


CONCLUSIONS
Cardiac 18F-FDG uptake was lower in patients receiving bezafibrate and levothyroxine and higher in patients receiving benzodiazepines. If further confirmed by prospectively designed studies, manipulation of these drugs may represent tools for optimized PET/CT imaging.
Israel
Ora
O
Department of Nuclear Medicine, Rambam Health Care Campus, Haifa, Israel. o_israel@rambam.health.gov.il
Weiler-Sagie
Michal
M
Rispler
Shmuel
S
Bar-Shalom
Rachel
R
Frenkel
Alex
A
Keidar
Zohar
Z
Bar-Shalev
Avi
A
Strauss
H William
HW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism; D001569:Benzodiazepines / Q000009:adverse effects; D001629:Bezafibrate / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006321:Heart / Q000000981:diagnostic imaging*; D006331:Heart Diseases / Q000000981:diagnostic imaging* / Q000378:metabolism*; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009206:Myocardium / Q000378:metabolism*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D013974:Thyroxine / Q000009:adverse effects; D014057:Tomography, X-Ray Computed; D014915:Whole-Body Counting
D000960:Hypolipidemic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D001569:Benzodiazepines; D013974:Thyroxine; D001629:Bezafibrate